



## ASX ANNOUNCEMENT

### **VivaGel<sup>®</sup> condom approved for sale with launch imminent**

**Melbourne, Australia; 2 October 2014:** Starpharma (ASX:SPL, OTCQX:SPHY) today announced the inclusion of the VivaGel<sup>®</sup> condom in the Australian Register of Therapeutic Goods (ARTG), the final step ahead of market launch in Australia.

Starpharma's partner in innovating and bringing this product to market, Ansell (ASX:ANN), has made the necessary preparations, including manufacture of launch supplies, and will launch the VivaGel<sup>®</sup> condom under the LifeStyles<sup>®</sup> Dual Protect<sup>™</sup> name in Australian retail outlets, including Woolworths stores around the country, during October.

The VivaGel<sup>®</sup> condom is a world-first product based on innovative Australian technology. It is the only condom of its type, providing barrier protection and also incorporating an antiviral compound (VivaGel<sup>®</sup>) in the lubricant. Australian consumers will be the first globally to access this innovative product discovered and developed in Australia.

LifeStyles<sup>®</sup> Dual Protect<sup>™</sup> condoms will carry the VivaGel<sup>®</sup> brand and Starpharma will receive royalties based on sales.

Starpharma Chief Executive Officer, Dr Jackie Fairley, said: "We are pleased to achieve this final milestone ahead of launch. We have been working closely with Ansell on the preparations for product rollout and both companies look forward to seeing the VivaGel<sup>®</sup> condom on Australian retail shelves in the coming weeks.

"Following certification of the VivaGel<sup>®</sup> condom by the TGA, there was extensive global media coverage and strong commercial and consumer interest in the product. The reaction on social media was quite extraordinary with the product reaching an audience of more than 10 million in the days following the announcement through extensive positive social media commentary. This overwhelmingly positive sentiment is in keeping with the strong consumer appeal identified in formal market research.

"The launch of the LifeStyles<sup>®</sup> Dual Protect<sup>™</sup> condom will represent the first marketed product for Starpharma's VivaGel<sup>®</sup> franchise, and the first of three women's health and sexual wellness VivaGel<sup>®</sup> products that are in various advanced stages of development and commercialisation" she said.

Ansell VP of Sales and Marketing for Asia Pacific, Chris Kalaitzis, said: "Ansell is already in the advanced stages of launch preparation and looks forward to the imminent launch of this innovative product, with LifeStyles<sup>®</sup> Dual Protect<sup>™</sup> condoms expected on retail shelves in Australia in October."

LifeStyles<sup>®</sup> Dual Protect<sup>™</sup> condoms are lubricated with VivaGel<sup>®</sup> lubricant, which contains the patented antiviral agent, astodimer sodium (referred to as VivaGel<sup>®</sup>).

VivaGel® is an antiviral compound that has been shown in laboratory studies to achieve viral inactivation rates of up to 99.9%.

As well as appearing on retail shelves, Ansell will also promote the LifeStyles® Dual Protect™ condoms on its website. For further details go to <http://www.ansellcondoms.com.au/>

-ENDS-



*LifeStyles® and Dual Protect™ are trademarks owned by Ansell Limited or one of its affiliates. VivaGel® is a registered trademark owned by Starpharma Pty Ltd.*

#### ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead products are based on VivaGel® (SPL7013, astodimer sodium), a proprietary dendrimer which is a potent microbicidal agent. VivaGel® formulated as a water based gel and delivered vaginally is under clinical development for the management and prevention of bacterial vaginosis (BV). Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries, Inc., (TSE: JP3192800005) to market a value-added, VivaGel® condom. Okamoto is the market leader for condoms sold in Japan, which is the world's second largest condom market. Ansell manufactures and sells leading condom brands worldwide, including LifeStyles®, ZERO® and SKYN®.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. A number of dendrimer-enhanced, or DEP™ versions of existing drugs are under development. The most advanced of these is DEP™ docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere®), which is in clinical development. In preclinical studies DEP™ docetaxel has shown significant tumour-targeting and superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including global leader Adama (formerly Makhteshim Agan) as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

## FOR FURTHER INFORMATION

### Media:

#### **Buchan Consulting**

Rebecca Wilson

Mob: +61 417 382 391

[rwilson@buchanwe.com.au](mailto:rwilson@buchanwe.com.au)

Gabriella Hold

+61 3 9866 4722

[ghold@buchanwe.com.au](mailto:ghold@buchanwe.com.au)

### Starpharma:

Dr Jackie Fairley, Chief Executive Officer

+61 3 8532 2704

Nigel Baade, CFO and Company Secretary

[Investor.relations@starpharma.com](mailto:Investor.relations@starpharma.com)

[www.starpharma.com](http://www.starpharma.com)

### Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.